1![Microsoft WordFampridine FAMPYRA Biogen IdecPSD FINAL.doc Microsoft WordFampridine FAMPYRA Biogen IdecPSD FINAL.doc](https://www.pdfsearch.io/img/37cbe45b75f4c42a32956611856b1f9c.jpg) | Add to Reading ListSource URL: www.pbs.gov.auLanguage: English - Date: 2014-10-01 21:56:22
|
---|
2![Clinical Commissioning Policy Statement: Fampridine for Multiple Sclerosis (MS) April 2013 Clinical Commissioning Policy Statement: Fampridine for Multiple Sclerosis (MS) April 2013](https://www.pdfsearch.io/img/15f834b2503c0de7273eaabfc8fdda83.jpg) | Add to Reading ListSource URL: www.england.nhs.ukLanguage: English - Date: 2014-08-12 08:05:39
|
---|
3![ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1
This medicinal product is subject to additional monitoring. This will allow quick identification of ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1
This medicinal product is subject to additional monitoring. This will allow quick identification of](https://www.pdfsearch.io/img/515212c8487ddc4f004ba5e4b540591e.jpg) | Add to Reading ListSource URL: www.ema.europa.euLanguage: English - Date: 2014-12-09 11:55:19
|
---|
4![Acknowledgement We acknowledge and pay respect to the traditional custodians past and present on whose lands we meet today. We acknowledge the deep feelings of attachment Acknowledgement We acknowledge and pay respect to the traditional custodians past and present on whose lands we meet today. We acknowledge the deep feelings of attachment](https://www.pdfsearch.io/img/4365a6b291afca765befcf3415ec586e.jpg) | Add to Reading ListSource URL: www.mssociety.org.auLanguage: English - Date: 2015-02-08 17:33:15
|
---|
5![HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AMPYRA safely and effectively. See full prescribing information for AMPYRA. AMPYRA® (dalfampridine) Extended Releas HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AMPYRA safely and effectively. See full prescribing information for AMPYRA. AMPYRA® (dalfampridine) Extended Releas](https://www.pdfsearch.io/img/6804b0509150fb055fca0715c88abd48.jpg) | Add to Reading ListSource URL: ampyra.comLanguage: English - Date: 2014-04-30 10:43:13
|
---|
6![](https://www.pdfsearch.io/img/a81cdf9a14460477abfab303858eea2c.jpg) | Add to Reading ListSource URL: www.england.nhs.ukLanguage: English - Date: 2013-08-13 12:09:51
|
---|
7![Microsoft Word - CSRO-FACTSHEET Microsoft Word - CSRO-FACTSHEET](https://www.pdfsearch.io/img/1885e9af2530876c2f3f112242ae6921.jpg) | Add to Reading ListSource URL: www.csro.comLanguage: English - Date: 2012-04-11 17:41:36
|
---|
8![Role of Kv1 Potassium Channels in Regulating Dopamine Release and Presynaptic D2 Receptor Function Philippe Martel, Damiana Leo, Stephanie Fulton, Maxime Be´rard, Louis-Eric Trudeau* Department of Pharmacology, Faculty Role of Kv1 Potassium Channels in Regulating Dopamine Release and Presynaptic D2 Receptor Function Philippe Martel, Damiana Leo, Stephanie Fulton, Maxime Be´rard, Louis-Eric Trudeau* Department of Pharmacology, Faculty](https://www.pdfsearch.io/img/1e9a5c0a704bdd39bed6f1a3b081d8a2.jpg) | Add to Reading ListSource URL: www.mapageweb.umontreal.caLanguage: English - Date: 2011-05-27 23:33:04
|
---|
9![Today’s date Plan name Plan address Re: (Claimant’s name, claim #) Dear Sir or Ms.: This is an appeal for reconsideration of (____your denial of coverage/pre-authorization, Today’s date Plan name Plan address Re: (Claimant’s name, claim #) Dear Sir or Ms.: This is an appeal for reconsideration of (____your denial of coverage/pre-authorization,](https://www.pdfsearch.io/img/bb1c617f1a2850460fa96c930a30f5f2.jpg) | Add to Reading ListSource URL: www.nationalmssociety.orgLanguage: English - Date: 2014-09-11 11:12:38
|
---|
10![US EPA - Reregistration Eligibility Decision for 4-aminopyridine US EPA - Reregistration Eligibility Decision for 4-aminopyridine](https://www.pdfsearch.io/img/779baaa68de712587aba2ce9de3677c5.jpg) | Add to Reading ListSource URL: www.epa.govLanguage: English - Date: 2007-12-04 13:56:49
|
---|